Mass Tort Advertising Campaign
Ozempic and other semaglutide-based medications manufactured by Novo Nordisk have become the subject of growing plaintiff-side litigation tied to serious gastrointestinal injuries — specifically gastroparesis, ileus, and bowel obstruction. As prescriptions for this class of GLP-1 receptor agonists expanded dramatically beyond their original diabetic patient base, so did reports of severe, sometimes hospitalization-requiring digestive complications that plaintiffs allege were inadequately disclosed.
For plaintiff firms evaluating paid acquisition, this tort presents a well-defined injury profile, a recognizable brand name with massive consumer awareness, and an intake window that is currently open. The combination of a household-name drug, serious documented injuries, and a large exposed population makes semaglutide one of the more actionable advertising opportunities in the current mass tort landscape.
Litigation against Novo Nordisk centers on claims that semaglutide — the active ingredient in Ozempic and related branded products — caused or contributed to gastroparesis (severely delayed gastric emptying), ileus (paralysis of the intestines), and bowel obstruction in patients who used the drug. These are not minor side effects; they are debilitating, often requiring emergency intervention or inpatient hospitalization, and plaintiffs allege the risks were not adequately communicated at the time of prescribing.
Intake is currently open, and plaintiff firms are actively building dockets. The injury set is medically distinct and documentable — hospital records, imaging, and gastroenterology notes create a paper trail that supports case evaluation. With Novo Nordisk as the named manufacturer and a drug that remains widely prescribed and culturally prominent, the litigation has the profile characteristics that sustain a long-running, high-volume acquisition campaign.
Semaglutide's brand recognition is a creative asset. Unlike many mass torts where the product name requires explanation, Ozempic is one of the most talked-about medications in recent memory — which means ad creative can lead with the drug name and immediately achieve recognition without education overhead. The creative angle pivots quickly from recognition to consequence: users who developed serious stomach or intestinal problems, needed hospitalization, or were diagnosed with gastroparesis or a bowel condition after taking the medication. That pivot — from a drug they know to an injury they lived — is where engagement happens on Meta placements.
Audience targeting layers naturally here. We build around age and demographic signals consistent with the GLP-1 prescribing population, layered with interest and behavioral signals tied to digestive health conditions and medication management. Intake qualification is structured to surface the hospitalization and diagnosis data points early in the funnel, so firms receive leads pre-screened against the strong-case criteria before a case manager touches them. For firms running high volume, we can build separate creative tracks for the core hospitalized gastroparesis audience and a softer track for the borderline ER-visit population, keeping cost-per-qualified-lead efficient across both segments.
Mass Tort Ad Agency runs Ozempic / Semaglutide campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.
We build, run, and qualify Ozempic / Semaglutide claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.
Book a strategy call